AU2006206738A1 - Mitotic kinesin inhibitors - Google Patents

Mitotic kinesin inhibitors Download PDF

Info

Publication number
AU2006206738A1
AU2006206738A1 AU2006206738A AU2006206738A AU2006206738A1 AU 2006206738 A1 AU2006206738 A1 AU 2006206738A1 AU 2006206738 A AU2006206738 A AU 2006206738A AU 2006206738 A AU2006206738 A AU 2006206738A AU 2006206738 A1 AU2006206738 A1 AU 2006206738A1
Authority
AU
Australia
Prior art keywords
alkyl
cycloalkyl
aryl
heterocyclyl
ros
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006206738A
Other languages
English (en)
Inventor
Paul J. Coleman
George D. Hartman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2006206738A1 publication Critical patent/AU2006206738A1/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: MERCK & CO., INC.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2006206738A 2005-01-19 2006-01-13 Mitotic kinesin inhibitors Abandoned AU2006206738A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64493305P 2005-01-19 2005-01-19
US60/644,933 2005-01-19
PCT/US2006/001364 WO2006078574A2 (en) 2005-01-19 2006-01-13 Mitotic kinesin inhibitors

Publications (1)

Publication Number Publication Date
AU2006206738A1 true AU2006206738A1 (en) 2006-07-27

Family

ID=36692758

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006206738A Abandoned AU2006206738A1 (en) 2005-01-19 2006-01-13 Mitotic kinesin inhibitors

Country Status (7)

Country Link
US (1) US20080102068A1 (https=)
EP (1) EP1856128A4 (https=)
JP (1) JP4545196B2 (https=)
CN (1) CN101107253A (https=)
AU (1) AU2006206738A1 (https=)
CA (1) CA2595127A1 (https=)
WO (1) WO2006078574A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
WO2009001214A2 (en) * 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20130331294A1 (en) 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
NZ602089A (en) 2010-02-17 2014-05-30 Takeda Pharmaceutical Heterocyclic compounds having cell division cycle 7 inhibitory activity
JP2013523867A (ja) * 2010-04-15 2013-06-17 ノバルティス アーゲー Ｋｓｐ阻害剤としてのトリアゾール化合物
EP2558452A2 (en) * 2010-04-15 2013-02-20 Novartis AG Oxazole and thiazole compounds as ksp inhibitors
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
MA46228A (fr) * 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
BR112019012106A2 (pt) 2016-12-15 2019-10-29 Janssen Pharmaceutica Nv inibidores de azepano de interação menin-mill
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
AU2020409437A1 (en) * 2019-12-18 2022-07-14 Universite De Montreal Modulators of Cullin 3 adaptor KBTBD4 as anti-cancer compounds
JP7554829B2 (ja) 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． 置換直鎖スピロ誘導体
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE327224T1 (de) * 1999-10-27 2006-06-15 Cytokinetics Inc Chinazolinone benutzende verfahren und zusammenstellungen
AU2002364128B2 (en) * 2001-12-06 2008-03-06 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US7378411B2 (en) * 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
US7262187B2 (en) * 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor
US20050107404A1 (en) * 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors
CA2489562A1 (en) * 2002-07-08 2004-01-15 Merck & Co., Inc. Mitotic kinesin binding site
WO2004064741A2 (en) * 2003-01-17 2004-08-05 Cytokinetics Inc. Compounds, compositions, and methods
JP3947758B2 (ja) * 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用

Also Published As

Publication number Publication date
JP2008527038A (ja) 2008-07-24
WO2006078574A3 (en) 2007-03-22
JP4545196B2 (ja) 2010-09-15
CN101107253A (zh) 2008-01-16
US20080102068A1 (en) 2008-05-01
CA2595127A1 (en) 2006-07-27
WO2006078574A2 (en) 2006-07-27
EP1856128A2 (en) 2007-11-21
EP1856128A4 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
AU2006206738A1 (en) Mitotic kinesin inhibitors
US7629373B2 (en) Mitotic kinesin inhibitors
AU2004305069C1 (en) Mitotic kinesin inhibitors
US20080045492A1 (en) Mitotic Kinesin Inhibitors
US7632839B2 (en) Mitotic kinesin inhibitors
EP1851213A2 (en) Mitotic kinesin inhibitors
US20090124641A1 (en) Mitotic Kinesin Inhibitors
EP1765830B1 (en) Mitotic kinesin inhibitors
WO2006007496A2 (en) Mitotic kinesin inhibitors
US7732472B2 (en) Mitotic kinesin inhibitors
CA2547746A1 (en) Mitotic kinesin inhibitors
WO2006023083A1 (en) Mitotic kinesin inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application